SynthesisJournal of neurology2025
Comparative efficacy and safety of different durations of dual antiplatelet therapy in acute minor non-cardioembolic stroke: a systematic review and network meta-analysis.
Synthesis in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Optimal pharmacological therapy for minor acute ischemic stroke: a network meta-analysis.Frontiers in neurologyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInternational guidelines recommend short-course dual antiplatelet therapy (DAPT) for secondary prevention in patients with acute minor stroke. However, the optimal duration of such therapy remains unclear. This review aims to evaluate and compare the efficacy and safety of different DAPT durations in the secondary prevention of acute minor ischemic stroke.
methodsThe present study systematically searched PubMed, Embase (via Ovid), Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and ClinicalTrials.gov to identify relevant randomized-controlled trials. The primary outcome was the incidence of all recurrent strokes. Data synthesis was performed through network meta-analysis and paired meta-analysis methodologies.
resultsA total of 7 studies with 34,646 participants were included. Compared with aspirin alone, each course of DAPT reduced the risk of recurrent stroke but increased the risk of bleeding: aspirin-clopidogrel 21 day DAPT (OR 0.75,95% CI 0.66-0.85)/(OR 1.48, 95% CI 1.16-1.89); aspirin-ticagrelor 30 day DAPT (OR 0.81,95% CI 0.70-0.95)/(OR 3.98,95% CI 1.74-9.10); aspirin-clopidogrel 90 day DAPT (OR 0.75,95% CI 0.60-0.93)/(OR 2.02, 95% CI 1.42-2.88). Compared with aspirin-clopidogrel 21 day DAPT, aspirin-ticagrelor 21 day DAPT was more efficacious with an increased risk of bleeding (OR 0.78,95% CI 0.65-0.92)/(OR 1.86, 95% CI 1.39-2.49). Network meta-analysis showed that aspirin-clopidogrel 21 day DAPT had the best risk-benefit profile, followed by aspirin-ticagrelor 21 day DAPT and aspirin-clopidogrel 90 day DAPT, with aspirin alone being the least effective.
conclusionsThe risk-benefit profile of 21 day DAPT with aspirin-clopidogrel was superior to that of other short-course DAPTs.
Indexed as
Identifiers
40550925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.